Plasma ACE2 activity is persistently elevated following SARS-CoV-2 infection: implications for COVID-19 pathogenesis and consequences

Sheila K Patel; Jennifer A Juno; Wen Shi Lee; Kathleen M Wragg; P Mark Hogarth; Stephen J Kent; Louise M Burrell

doi:10.1183/13993003.03730-2020

Plasma ACE2 activity is persistently elevated following SARS-CoV-2 infection: implications for COVID-19 pathogenesis and consequences

Eur Respir J. 2021 May 13;57(5):2003730. doi: 10.1183/13993003.03730-2020. Print 2021 May.

Authors

Sheila K Patel^{1

2}, Jennifer A Juno^{3

2}, Wen Shi Lee³, Kathleen M Wragg³, P Mark Hogarth⁴, Stephen J Kent^{3

5}, Louise M Burrell^{6

5}

Affiliations

¹ Dept of Medicine, Austin Health, University of Melbourne, Melbourne, Australia.
² Contributed equally.
³ Dept of Microbiology and Immunology, University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne, Australia.
⁴ Immune Therapies Group, Burnet Institute, Melbourne, Australia.
⁵ S.J. Kent and L.M. Burrell contributed equally to this article as lead authors and supervised the work.
⁶ Dept of Medicine, Austin Health, University of Melbourne, Melbourne, Australia l.burrell@unimelb.edu.au.

Abstract

Plasma ACE2 activity is persistently elevated in patients after COVID-19 infection. Larger studies are needed to determine if this identifies people at risk of prolonged illness following COVID-19. https://bit.ly/2XQlrYF

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Antiviral Agents
COVID-19*
Humans
Peptidyl-Dipeptidase A* / metabolism
Renin-Angiotensin System
SARS-CoV-2

Substances

Antiviral Agents
Peptidyl-Dipeptidase A